Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1′-pyrrolidinone or P2-tris-tetrahydrofuran

Extreme drug resistant mutant of HIV-1 protease (PR) bearing 20 mutations (PR20) has been studied with the clinical inhibitor amprenavir (1) and two potent antiviral investigational inhibitors GRL-02031 (2) and GRL-0519 (3). Clinical inhibitors are >1000-fold less active on PR20 than on wild type...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Agniswamy, Johnson, Shen, Chen-Hsiang, Wang, Yuan-Fang, Ghosh, Arun K., Rao, Kalapala Venkateswara, Xu, Chun-Xiao, Sayer, Jane M., Louis, John M., Weber, Irene T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3719844/
https://ncbi.nlm.nih.gov/pubmed/23590295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm400231v
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados